Close Menu

More articles about Molecular Diagnostics

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

Health systems' molecular testing labs haven't had to cut back on genomic profiling for cancer patients yet but may need to accommodate COVID-19 testing if needed.

SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.

Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.

Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.

The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.

The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

The company filed the application based on the PAOLA-1 data, which showed HRD-positive ovarian cancer patients saw pronounced benefit from the combo.

Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.

Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.

The foundation-funded initiative from Jackson Laboratories has advanced a model for educating oncologists and providing access to tumor genomic profiling in the community setting.

Qiagen obtained CE marking for its Therascreen PIK3CA RGQ PCR kit to aid in identifying breast cancer patients with a PIK3CA mutation.

Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways. 

The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.

The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health. 

Benefit was seen for patients with high TMB on Keytruda, with ERBB2 amplifications on Perjeta and Herceptin, and with BRAF mutations on Cotellic plus Zelboraf.

Myriad filed an sPMA for myChoice CDx despite GSK's confidence that Zejula will be approved in newly diagnosed ovarian cancer regardless of biomarker status.

Pages